Search Results
Sep 04, 2026, 07:00 ET Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Sept. 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious
More news about: Insmed Incorporated
Sep 03, 2026, 07:00 ET Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026
(PAH)—BRIDGEWATER, N.J., Sept. 3, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious
More news about: Insmed Incorporated
Aug 26, 2026, 07:00 ET Insmed to Present at September 2026 Investor Conferences
BRIDGEWATER, N.J., Aug. 26, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious
More news about: Insmed Incorporated
Aug 24, 2026, 07:00 ET BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
Damage—BRIDGEWATER, N.J., Aug. 24, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious
More news about: Insmed Incorporated
Aug 06, 2026, 07:00 ET Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update
ARIKAYCE—BRIDGEWATER, N.J., Aug. 6, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious
More news about: Insmed Incorporated
Jul 23, 2026, 07:00 ET Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026
BRIDGEWATER, N.J., July 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious
More news about: Insmed Incorporated
Jul 16, 2026, 07:00 ET Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension
ET–BRIDGEWATER, N.J., July 16, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious
More news about: Insmed Incorporated
Jun 23, 2026, 07:00 ET Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory
BRIDGEWATER, N.J., June 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious
More news about: Insmed Incorporated
Jun 07, 2026, 23:08 ET STARTRADER lança 39 novas ações e ETFs dos EUA em setores que moldam o futuro dos mercados globais
tradicionais e a infraestrutura cripto regulada, enquanto KTOS acrescenta exposição às tecnologias de defesa autônoma e drones. Completando o lançamento, INSM, STRL e TME abrangem oportunidades de infraestrutura e aplicações, juntamente com seis ETFs temáticos regionais — Japão (EWJ), Coreia do Sul (EWY), Brasil
More news about: STARTRADER
Jun 07, 2026, 23:08 ET STARTRADER lanza 39 nuevas acciones estadounidenses y ETF en los sectores que definen el futuro de los mercados internacionales
de criptomonedas regulada, mientras que KTOS aumenta la exposición a las tecnologías autónomas de defensa y drones. Para completar el lanzamiento, INSM, STRL y TME abarcan las oportunidades relacionadas con la infraestructura y la aplicación, junto a seis ETF temáticos regionales —Japón (EWJ), Corea
More news about: STARTRADER
Jun 04, 2026, 07:00 ET Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., June 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious
More news about: Insmed Incorporated
May 28, 2026, 05:32 ET STARTRADER ने वैश्विक बाजारों के भविष्य को आकार देने वाले विभिन्न क्षेत्रों में 33 नए अमेरिकी स्टॉक और ETFs लॉन्च किए
क्षेत्र में लगातार प्रवाहित हो रही है।KTOS स्वायत्त रक्षा और ड्रोन टेक्नोलॉजियों के क्षेत्र में अनुभव प्रदान करता है। लॉन्च को पूरा करते हुए, INSM, STRL और TME इंफ्रास्ट्रक्चर और एप्लीकेशन के अवसरों के साथ-साथ ब्याज दर में बदलाव के दौरान यील्ड एंकर प्रदान करने वाले छह क्षेत्रीय थिमैटिक ETFs, जापान
More news about: STARTRADER
May 28, 2026, 02:46 ET 스타트레이더, 글로벌 시장의 미래를 이끄는 핵심 섹터에 걸쳐 미국 주식 및 ETF 33종 신규 추가
우주 경제 분야에서는 ASTS, RKLB, IRDM, SATS를 통해 위성 통신 및 저궤도 네트워크에 대한 투자 접근성을 제공하며, 이 분야에 대한 기관 자금 유입은 지속적으로 증가하고 있다.KTOS는 자율 방산 및 드론 기술 분야의 투자 기회를 제공한다. 여기에 INSM, STRL, TME가 인프라 및 응용 분야 기회를 더하며, 일본(EWJ), 한국(EWY), 브라질(EWZ), 인도(INDA), 중국(MCHI), 레버리지 기술(TQQQ) 등 6개 지역 테마 ETF와 금리 전환기의 수익 안정화 수단인 TLT까지 이번 라인업을 완성한다."이번
More news about: STARTRADER
May 27, 2026, 23:41 ET STARTRADER ra mắt 33 cổ phiếu Mỹ và ETF mới thuộc các lĩnh vực đang định hình tương lai của thị trường toàn cầu
tục đổ vào lĩnh vực này.KTOS mang đến khả năng tiếp cận lĩnh vực quốc phòng tự động hóa và công nghệ drone. Hoàn thiện thêm cho danh mục là INSM, STRL và TME — đại diện cho các cơ hội về hạ tầng và ứng dụng công nghệ — cùng với sáu ETF theo chủ đề khu vực gồm Nhật Bản (EWJ), Hàn Quốc (EWY), Brazil
More news about: STARTRADER
May 27, 2026, 23:40 ET STARTRADER、グローバル市場の未来を形づくる分野を網羅する米国株・ETF 33銘柄を新たに追加
ーク分野へのエクスポージャーを確保でき、同分野に対する機関投資家マネーの流入が続く中で、成長テーマへのアクセスを広げます。さらに、KTOSにより、自律型防衛技術やドローン関連分野への投資機会も提供されます。加えて、INSM、STRL、TMEはインフラおよびアプリケーション関連の機会をカバーし、日本（EWJ）、韓国（EWY）、ブラジル（EWZ）、インド（INDA）、中国（MCHI）、レバレッジド・テクノロジー（TQQQ）といった地域別テーマ型ETF 6本、さらに金利移行局面における利回りの軸となるTLTも追加されました。「今回の追加
More news about: STARTRADER
May 27, 2026, 07:00 ET Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference
BRIDGEWATER, N.J., May 27, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious
More news about: Insmed Incorporated
May 26, 2026, 04:04 ET STARTRADER Launches 39 New US Stocks and ETFs Across the Sectors Shaping the Future of Global Markets
traditional finance and regulated crypto infrastructure, while KTOS adds exposure to autonomous defense and drone technologies. Rounding out the launch, INSM, STRL, and TME cover infrastructure and application opportunities, alongside six regional thematic ETFs — Japan (EWJ), South Korea (EWY), Brazil (EWZ),
More news about: STARTRADER
May 26, 2026, 03:57 ET STARTRADER Launches 39 New US Stocks and ETFs Across the Sectors Shaping the Future of Global Markets
traditional finance and regulated crypto infrastructure, while KTOS adds exposure to autonomous defense and drone technologies. Rounding out the launch, INSM, STRL, and TME cover infrastructure and application opportunities, alongside six regional thematic ETFs — Japan (EWJ), South Korea (EWY), Brazil (EWZ),
More news about: STARTRADER
May 07, 2026, 07:00 ET Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
2026—BRIDGEWATER, N.J., May 7, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious
More news about: Insmed Incorporated
May 06, 2026, 16:30 ET Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis
—BRIDGEWATER, N.J., May 6, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious
More news about: Insmed Incorporated
May 04, 2026, 07:00 ET Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026
U.S.—BRIDGEWATER, N.J., May 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious
More news about: Insmed Incorporated
Apr 30, 2026, 07:00 ET Insmed to Present at May 2026 Investor Conferences
BRIDGEWATER, N.J., April 30, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious
More news about: Insmed Incorporated
Apr 23, 2026, 07:00 ET Insmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026
BRIDGEWATER, N.J., April 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious
More news about: Insmed Incorporated
Apr 07, 2026, 16:01 ET Insmed Provides Clinical Update on Phase 2b CEDAR Study
Brensocatib— BRIDGEWATER, N.J., April 7, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious
More news about: Insmed Incorporated
Mar 23, 2026, 07:00 ET Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease
BRIDGEWATER, N.J., March 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious
More news about: Insmed Incorporated